LOGIN  |  REGISTER
Cue Biopharma

TruBridge Announces Participation in 2024 RBC Capital Markets Global Healthcare Conference

May 08, 2024 | Last Trade: US$20.82 0.74 -3.43

MOBILE, Ala. / May 08, 2024 / Business Wire / TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced that management will participate in the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024, in New York, NY.

The fireside chat presentation by Chris Fowler, president and chief executive officer, and Vinay Bassi, chief financial officer, will begin at approximately 2:05 p.m. Eastern Time on Wednesday, May 15, 2024, and will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website www.trubridge.com.

About TruBridge

We are a trusted partner to more than 1,500 healthcare organizations with a broad range of technology-first solutions that address the unique needs and challenges of diverse communities, promoting equitable access to quality care and fostering positive outcomes. Our industry leading HFMA Peer Reviewed® suite of revenue cycle management (RCM) offerings combine unparalleled visibility and transparency to enhance productivity and support the financial health of healthcare organizations across all care settings. TruBridge has over four decades of experience in connecting providers, patients and communities with innovative solutions that create real value by supporting both the financial and clinical side of healthcare delivery. Our solutions champion end-to-end, data-driven patient journeys that support value-based care, improve outcomes, and increase patient satisfaction. We support efficient patient care with electronic health record (EHR) product offerings that successfully integrate data between care settings. Above all, we believe in the power of community and encourage collaboration, connection, and empowerment with our customers. We clear the way for care. For more information, please visit www.trubridge.com.

Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page